Suresh et al. (2020) The increased PD-L1 suppress anti-tumor immune responses. PERK signaling was found to suppress immune responses by increasing tumor-myeloid-derived suppressor cells (MDSC). PERK blockade transforms MDSC’s into myeloid cells that activate anti-tumor CD8+ T-cell immunity in the tumor microenvironment.  AMG-44, a PERK inhibitor, in combination with Anti-PD-L1 showed a synergistic anti-tumor effect in B16 tumor-bearing mice model (Figure 3) (Mohamed et al., 2020). This evidence concerns the gene CD8A and neoplasm.